Recombinant factor VIIa (eptacog alpha): A new therapeutic option for severe bleeding due to antibodies against a coagulation factor;Recombinantfactor VIIa (eptacog alfa): Nieuwe therapeutische optie bij patienten met een ernstige bloeding door antistoffen tegen een stollingsfactor

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 25, 1998, Pages 1464-1467

  Turkstra, F ^a   Levi, M ^a   Koopman, M M W ^a   Wester, J P J ^a   Stoutenbeek, C P ^a   Briet E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CASE REPORT; DRUG EFFECT; FEMALE; HEMOPHILIA A; HUMAN; MALE; TREATMENT OUTCOME;

ADULT; ANTIBODIES; BLOOD COAGULATION; FACTOR VIIA; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0032551085     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ludlam CA. Treatment of haemophilia. In: Poller L, Ludlam CA, editors. Recent advances in blood coagulation. New York: Churchill Livingstone, 1997:235-60.
2. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981;45:200-3.
3. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996;9:331-54.
4. Brouwer RE, Huisman MV, Feuth JDM, Meer FJM van der. Verworven hemofilie A. Ned Tijdschr Geneeskd 1997;141:1342-4.
5. Josso F, Prou-Wandle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh 1965;17(Suppl):35-44.
6. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 1995;74:7-17.
7. Cate H ten, Levi M, Hack CE. Nieuwe inzichten en Hypothesen ten aanzien van de bloedstolling in vivo Ned Tijdschr Geneeskd 1993;137:282-7.
8. A more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh 1975;34:869-72.
9. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202:498-9.
10. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996;26(Suppl 1):135-8.
11. Laurian Y, Goudemond J, Negrier C, Vicariot M, Marques-Verdier A, Fonlupt J, et al. Use of NovoSeven(r) as first line therapy for bleeding episodes in hemophiliacs with factor VIII or IX inhibitors (Nosepac study) Thromb Haemost 1997;77:85.
12. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997;78:1463-7.
13. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasia 1996;26(Suppl 1):124-30.
14. Rice KM, Savidge GF. NovoSeven (recombinant factor Vila) in centeral nervous systems bleeds. Haemostasis 1996;26(Suppl 1):131-4.
15. Cooper HA, Hoots WK, Shapiro A. Comparison of two doses of recombinant factor VIIa for producing hemostasis during and after surgery in patients with hemophilia A or B and inhibitors and patients with acquired inhibitors. Thromb Haemost 1997;77:167.
16. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996;26(Suppl 1):118-23.
17. DiMichele D. The use of recombinant factor VIIa for central catheter insertion: an international experience. Thromb Haemost 1997; 77:167.
18. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996;75:432-6.
19. Ingerslev J, Holm M, Christiansen K, Knudesen L. Activation marker F1+2 in patients with recombinant factor VIIa Thromb Haemost 1997;77:85.
20. Lund-Hansen T, NovoSeven - virus safety Haemostasis 1996; 26(Suppl 1):96-7
21. Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 1996;26(Suppl 1):155-8.
22. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, et al. Clinical experience with recombinant factor Vila in patients with thrombocytopenia. Haemostasis 1996;26(Suppl 1):159-64.
23. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost 1996;75:981-2.
24. Bernstein DE, Jeffers LJ, Erhardtsen E, Reddy KR, Bech RM Hedner U, et al. The use of recombinant factor Vila in advanced liver disease. Thromb Haemost 1997;77:85.